Farré Madulell E, Gascón Brustenga J, Valls Lolla M E, Corachán Cuyás M
Servicio de Medicina Tropical, Hospital Clínic, Barcelona.
Rev Clin Esp. 1998 Dec;198(12):815-7.
Imported malaria is an ever growing disease in our country because of the increase in travels to endemic tropical areas where this disease is endemic. Many patients, when they come to our hospitals infected with P. falciparum have already received drugs for this disease, either as prophylaxis or treatment, as it occurred in the cases reported here in the years 1995 and 1997, all of the spanish individuals who had travelled to or lived in African countries. To remark from our data the relevance of resistance to prophylactic and therapeutical agents in wide geographical areas, the frequent misuse of antimalarial drugs and complications that can emerge with the standard treatment for malaria. It all leads to the development of new therapeutic approaches for this potentially fatal infection. Based on the clinical efficiency in cases of politreated malaria cases, as well as for its safety in patients to whom first choice drugs cannot be administered (such as quinine), we stress the new therapy made up with the association atovaquone-proguanil.
由于前往疟疾流行的热带地区旅行的人数增加,输入性疟疾在我国已成为一种日益严重的疾病。许多感染恶性疟原虫的患者在来到我们医院时已经接受过针对这种疾病的药物治疗,无论是作为预防用药还是治疗用药,就像1995年和1997年这里报告的病例那样,所有前往非洲国家旅行或居住的西班牙人都是如此。从我们的数据中可以看出,在广泛的地理区域中,对预防和治疗药物产生耐药性、抗疟药物的频繁滥用以及疟疾标准治疗可能出现的并发症具有重要意义。所有这些都促使人们开发针对这种潜在致命感染的新治疗方法。基于对多次治疗的疟疾病例的临床疗效以及对无法使用首选药物(如奎宁)的患者的安全性,我们强调由阿托伐醌-氯胍联合组成的新疗法。